Brainstorm cell therapeutics announces the presentation of new analyses from the phase 3 trial of nurown® in als at the 4th annual als one research symposium

New york, nov. 29, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the phase 3 trial of nurown at the 4th annual als one research symposium. the presentation, which will be delivered tomorrow by dr. jonathan katz, a co-principal investigator on the trial and chair of the neurology department and director of the forbes norris als clinic at the california pacific medical center, showed that although the phase 3 trial did not reach statistical significance on the primary and secondary endpoints, pre-specified and post hoc analyses leveraging different methods of exploring the heterogeneity of baseline disease in the trial, revealed the potential for a meaningful treatment effect across endpoints when focusing on a subset of participants with less severe disease at baseline.
BCLI Ratings Summary
BCLI Quant Ranking